1/16/2024 | SP | New Issue: Barclays prices $639,000 phoenix autocallable notes tied to three stocks
|
10/26/2023 | SP | New Issue: GS Finance prices $2.62 million notes linked to basket of 43 stocks
|
8/17/2023 | SP | New Issue: GS Finance sells $778,000 buffered basket-linked notes on 44 stocks
|
7/11/2023 | SP | New Issue: GS Finance sells $1.34 million buffered basket-linked notes on basket of 44 stocks
|
8/19/2022 | SP | New Issue: Barclays sells $500,000 callable contingent coupon notes on Incyte
|
7/1/2022 | SP | New Issue: GS Finance sells $900,000 buffered basket-linked notes on 44 stocks
|
4/29/2022 | SP | New Issue: GS Finance sells $9.25 million basket-linked notes tied to 77 stocks
|
4/22/2022 | SP | New Issue: GS Finance sells $8 million basket-linked notes tied to 45 stocks
|
8/26/2021 | SP | New Issue: GS Finance prices $13.14 million leveraged basket-linked notes on 179 stocks
|
9/2/2020 | SP | New Issue: Goldman prices $1.2 million leveraged basket-linked notes on 20 stocks
|
4/24/2020 | SP | New Issue: Goldman prices $1.73 million leveraged basket-linked notes on 19 stocks
|
5/31/2019 | SP | Goldman amends Cusip for notes tied to basket of Russell 3000 stocks
|
5/30/2019 | SP | New Issue: CIBC sells $370,000 Raymond James Healthcare Top Selections notes on 15 stocks
|
5/30/2019 | SP | New Issue: CIBC sells $1.64 million Raymond James Healthcare Top Selections notes on 15 stocks
|
5/9/2019 | SP | New Issue: Goldman sells $1 million notes tied to basket of Russell 3000 stocks
|
3/6/2019 | SP | New Issue: Citigroup sells $500,000 autocallable equity-linked notes on four stocks
|
2/25/2019 | SP | New Issue: BMO sells $595,000 bullish enhanced return barrier notes on Raymond James top picks
|
2/25/2019 | SP | New Issue: BMO sells $398,000 bullish enhanced return barrier notes on Raymond James top picks
|
2/14/2019 | SP | Citigroup plans autocallable equity-linked notes tied to four stocks
|
1/23/2019 | SP | New Issue: BMO prices $19.72 million notes on Raymond James Best Picks for 2019
|
1/23/2019 | SP | New Issue: BMO prices $42.29 million notes on Raymond James Best Picks for 2019
|
12/27/2018 | SP | New Issue: BMO prices $39.76 million notes on Raymond James Best Picks for 2019
|
12/27/2018 | SP | New Issue: BMO prices $18.96 million notes on Raymond James Best Picks for 2019
|
10/31/2018 | SP | New Issue: BMO sells $292,000 notes on eight Raymond James biotechnology top picks
|
10/31/2018 | SP | New Issue: BMO sells $390,000 notes on eight Raymond James biotechnology top picks
|
10/31/2018 | SP | New Issue: CIBC sells $120,000 notes on Raymond James top pick healthcare stocks
|
10/31/2018 | SP | New Issue: CIBC sells $400,000 notes on Raymond James top pick healthcare stocks
|
10/18/2018 | SP | CIBC to price notes on 11 Raymond James top pick healthcare stocks
|
10/18/2018 | SP | CIBC plans notes on 11 Raymond James top pick healthcare stocks
|
10/11/2018 | SP | BMO plans notes due 2020 tied to Raymond James biotech top picks
|
10/11/2018 | SP | BMO to price notes due 2020 tied to Raymond James biotech top picks
|
10/8/2018 | SP | New Issue: BMO sells $1.23 million notes on eight Raymond James Biotechnology Sector top picks
|
10/8/2018 | SP | New Issue: BMO sells $1.02 million notes on eight Raymond James Biotechnology Sector top picks
|
4/2/2018 | SP | New Issue: CIBC sells $495,000 notes on eight Raymond James top pick healthcare stocks
|
4/2/2018 | SP | New Issue: CIBC sells $285,000 Raymond James Healthcare Top Selections notes on 16 stocks
|
4/2/2018 | SP | New Issue: CIBC sells $548,000 notes on eight Raymond James top pick healthcare stocks
|
3/20/2018 | SP | CIBC plans notes on eight Raymond James top pick healthcare stocks
|
3/20/2018 | SP | CIBC to price notes on eight Raymond James top pick healthcare stocks
|
3/20/2018 | SP | CIBC plans Raymond James Healthcare Top Selections notes on 16 stocks
|
3/20/2018 | SP | CIBC to price notes on 16 Raymond James top pick healthcare stocks
|
3/19/2018 | SP | New Issue: Credit Suisse sells $500,000 contingent coupon autocallable yield notes on three stocks
|
3/16/2018 | SP | New Issue: HSBC prices $3.2 million of autocallable notes linked to Incyte
|
3/16/2018 | SP | New Issue: Credit Suisse sells $500,000 contingent coupon autocallable yield notes on three stocks
|
2/9/2018 | SP | New Issue: Citigroup sells $572,000 autocallable equity-linked notes tied to pharma stocks
|
8/29/2017 | SP | New Issue: JPMorgan sells $1.96 million contingent income autocallables on Incyte
|
8/21/2017 | SP | JPMorgan aims to price contingent income autocallables tied to Incyte
|
6/14/2017 | SP | New Issue: JPMorgan sells $1 million contingent buffered notes on basket of seven stocks
|
5/30/2017 | SP | JPMorgan plans capped contingent buffered notes linked to seven stocks
|
2/21/2017 | CVLM | Incyte agrees to exchange some 0.375% convertibles, 1.25% convertibles
|
8/22/2016 | PP | Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
|
8/22/2016 | CV | Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
|
1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
4/15/2015 | SP | New Issue: UBS prices $175,000 trigger phoenix autocallables linked to Incyte
|
4/15/2015 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Incyte
|
2/24/2015 | SP | New Issue: Barclays prices $729,000 7.5% airbag autocallable yield notes on Incyte
|
2/18/2015 | SP | Barclays to price 7%-8.25% airbag autocallable yield notes on Incyte
|
2/12/2015 | CV | Market Commentary: Tesla drops outright, narrowly mixed on hedge after disappointing earnings; Nvidia expands
|
12/17/2014 | SP | New Issue: Citigroup prices $4.48 million 8.9% airbag autocallables linked to Incyte
|
12/10/2014 | SP | Citigroup plans 6.55%-8.55% airbag autocallables linked to Incyte
|
12/1/2014 | SP | New Issue: RBC prices $2.12 million buffered optimization notes tied to health care stocks
|
8/1/2014 | SP | New Issue: JPMorgan prices $5.34 million 7% airbag autocallables linked to Incyte
|
7/23/2014 | SP | JPMorgan to price 6%-8% airbag autocallables linked to Incyte
|
6/17/2014 | SP | New Issue: UBS prices $1.13 million contingent absolute return autocallables linked to Incyte
|
6/10/2014 | SP | UBS plans contingent absolute return autocallables linked to Incyte
|
4/30/2014 | SP | New Issue: Deutsche Bank prices $7.08 million 10.5% airbag autocallables on Incyte
|
4/24/2014 | SP | Deutsche to price 9%-11.6% airbag autocallables linked to Incyte
|
3/19/2014 | SP | New Issue: UBS sells $6.2 million 10.22% airbag autocallables linked to Incyte
|
3/12/2014 | SP | UBS to price 8.15%-10.15% airbag autocallables linked to Incyte
|
11/14/2013 | CV | Incyte greenshoe lifts two-part convertibles deal to $750 million
|
11/8/2013 | CV | Market Commentary: Midday Commentary: Incyte's two-tranche deal prices, trades up; MolyCorp falls on earnings
|
11/8/2013 | CV | New Issue: Incyte sells $700 million of convertible senior notes in two tranches
|
11/8/2013 | CV | Market Commentary: Incyte's $700 million two-tranche deal prices, trades up; Molycorp falls on wider loss
|
11/7/2013 | CV | Market Commentary: ServiceNow holds up on debut; InvenSense adds; planned Incyte looks cheap; earnings eyed
|
11/6/2013 | CV | Incyte to price $700 million of convertible senior notes in two parts
|
11/6/2013 | CV | Market Commentary: New Layne Christensen holds up on debut; planned ServiceNow looks cheap; Incyte on tap
|
9/17/2013 | CVLM | Incyte exchanges $37.29 million 4.75% convertibles for stock, cash
|
8/13/2013 | SP | New Issue: UBS prices $1.86 million 8.54% airbag autocallable notes linked to Incyte
|
8/6/2013 | SP | UBS to price 7.25%-9.25% airbag autocallables linked to Incyte
|
6/5/2013 | CVLM | Incyte agrees to exchange $37.46 million 4.75% convertibles due 2015
|
5/3/2011 | CV | Market Commentary: Mylan off outright, expands on hedge; Incyte premium comes in; Alaska Communications on tap
|
9/13/2010 | CV | Market Commentary: Hertz comes 'in' a little on swap with better Dollar Thrifty bid; Level 3, Volcano on tap
|
8/2/2010 | CV | Market Commentary: Newell Rubbermaid adds more than 2 points of premium; Teleflex plans $350 million deal
|
4/23/2010 | CV | Market Commentary: Health care names recover; investment-grade names in focus; Incyte, Textron strengthen
|
2/23/2010 | CV | Incyte holders convert $16.9 million 3.5% notes ahead of redemption
|
2/1/2010 | CV | Market Commentary: Convertibles firmer; USEC better on Obama comments; Newmont Mining in trade as gold gains
|
1/28/2010 | CV | Incyte to redeem all of its 3.5% convertibles due 2011 on Feb. 22
|
1/15/2010 | CV | Market Commentary: SanDisk, Bunge up on yield trades; Micron Technology slips with stock; Incyte down, active
|
11/5/2009 | CV | Incyte retires $212.3 million of two series of 3.5% convertible notes
|
11/5/2009 | CV | Market Commentary: Ford active, weaker after debut; Jakks Pacific trades over par; MasTec quiet; Incyte gains
|
11/2/2009 | CV | Market Commentary: YRC jumps on exchange; Vornado up on tender; Human Genome surges on lupus drug; Ford to price
|
10/6/2009 | CV | Market Commentary: MannKind drops on partnership deal delay; Medtronic, Transocean gain; Avis, AirTran plan deals
|
10/5/2009 | CV | Market Commentary: UAL adds amid quiet trading; AMD gains; Medtronic up in solid volume; trading breadth narrow
|
9/30/2009 | CV | Incyte buys back $186.2 million in two series of 3.5% convertibles
|
9/30/2009 | SS | Incyte investors led by Baker Brothers buy additional 2 million shares
|
9/30/2009 | CV | Incyte greenshoe exercised, raising convertibles to $400 million
|
9/25/2009 | CV | Market Commentary: Incyte trades up smartly on debut; AMR steady to stronger; Gaylord, PHH tracking over par
|
9/24/2009 | CV | New Issue: Incyte prices upsized $350 million of six-year convertibles to yield 4.75%, up 30%
|
9/24/2009 | CV | Market Commentary: Gaylord, PHH, ATP Oil slip from highs with stocks; Incyte looks less cheap as terms reset
|
9/23/2009 | CV | Market Commentary: AMR, Goodrich Petroleum gain on debuts; Gaylord Entertainment, PHH price upsized deals
|
9/22/2009 | CV | Incyte to price $250 million six-year convertible notes to yield 5%-5.5%, up 22.5%-27.5%
|
9/22/2009 | CV | Market Commentary: AMR adds in gray, then upsizes; MannKind gains more: Goodrich, ATP, Incyte, Gaylord to price
|
9/22/2009 | CV | Incyte plans to retire two series of 3.5% convertibles due 2011
|
3/6/2009 | CVHY | Incyte files $150 million shelf
|
3/2/2009 | SS | Incyte investors led by Baker Brothers buy more shares
|
12/23/2008 | SS | Incyte investors led by Baker Brothers buy additional shares
|
2/1/2008 | SS | Baker Brothers buy more shares of Incyte
|
1/14/2008 | SS | Baker Brothers continue to build stake in Incyte
|
1/8/2008 | SS | Baker Brothers continue to invest in Incyte
|
12/12/2007 | SS | Baker Brothers report 10.2% ownership of Incyte
|
10/10/2007 | PP | New Issue: Incyte sells convertible note for $10 million
|
11/3/2006 | BT | JMP keeps Incyte at market outperform
|
9/26/2006 | BTCV | Incyte greenshoe exercised, upping convertibles to $151.8 million
|
9/26/2006 | BTCV | Incyte calls 5.5% convertibles due 2007
|
9/21/2006 | BT | Market Commentary: Nycomed deal seen coming on Altana buy; Warner Chilcott slips on debut; Serono up on buyout
|
9/21/2006 | CV | Market Commentary: Incyte's new notes rise as old paper crumples; Priceline deal seen as rich; Novell gains on default potential
|
9/21/2006 | BTCV | New Issue: Incyte reoffers $132 million 4.4-year 3.5%, up 126.2% convertibles within talk, at 78
|
9/20/2006 | BTCV | Incyte to call 5.5% convertibles due 2007
|
9/20/2006 | BT | Market Commentary: Incyte pitches deeply discounted drive-by convertible; Genta down 32% on PIPE; Adolor rises
|
9/20/2006 | CV | Market Commentary: First Industrial, BioMed higher on debuts; XM gains further; Red Hat climbs with stock; Incyte plans deal
|
9/20/2006 | BTCV | New Issue: Incyte to offer $132 million 4.4-year, 3.5%, up 126.2% convertibles at discounted 77-79
|
7/27/2006 | BT | Incyte second-quarter revenues up at $6.9 million
|
7/27/2006 | BT | JMP reiterates Incyte at market outperform
|
6/7/2006 | BT | Incyte tests INCB13739 in phase 1 diabetes study
|
6/7/2006 | BT | Market Commentary: Antigenics up 11% on data; Discovery Labs dives 19%; Incyte up; VaxGen slides
|
5/10/2006 | BT | Incyte starts phase 1 study of HIV treatment
|
5/4/2006 | BT | Incyte says first-quarter revenue more than doubles, updates key programs
|
5/4/2006 | BT | Market Commentary: Bausch & Lomb stock sinks after buyback offering to avoid default; ImmunoGen stock up on earnings
|
4/6/2006 | CV | Market Commentary: Allergan new deal stumbles in the gray; Annaly offering seen as hedge play; Cell Therapeutics plans deal
|
4/4/2006 | BT | JMP downgrades Incyte to market outperform
|
4/3/2006 | BT | Incyte sees increase in pancreatic inflammation, ends DFC as a treatment for HIV
|
4/3/2006 | BT | Market Commentary: Epix up 21% on Predix buy; Incyte falls 41%; Medarex off; Inhibitex plunges 66%; StemCells dives
|
2/16/2006 | BT | Incyte says 2005 revenue down 50% to $7.8 million, predicts $20-$25 million for 2006
|
2/8/2006 | BT | Market Commentary: Pfizer news sparks buyout buzz; Immtech falls; Alkermes up; Icos off; Alexion higher; Oscient down
|
1/18/2006 | BT | JMP says select small-, mid-cap biotech stocks look promising
|
11/22/2005 | BT | JMP reiterates Incyte at buy
|
11/21/2005 | BTPP | Pfizer, Incyte establish license agreement for CCR2 antagonists; Incyte may gain $783 million
|
11/21/2005 | BT | Thomas Weisel reiterates Incyte at outperform
|
11/21/2005 | BT | Market Commentary: Incyte zooms on R&D pact with Pfizer; Medicis, Mentor, Allergan, Inamed tangle in merger scuffle
|
11/21/2005 | CV | Market Commentary: GM mixed in light trade, Ford flat, Incyte gains on Pfizer pact, but SFBC falls
|
11/1/2005 | BT | JMP reiterates Incyte at strong buy
|
11/1/2005 | BTCV | Incyte pays $35.8 million to buy back 5.5% convertibles
|
9/29/2005 | BT | Incyte price target reduced by JMP
|
9/29/2005 | BT | Market Commentary: Genomic, Avalon sink after IPOs price at low end; Forest, Cypress dive; SkinMedica's IPO on deck
|
9/28/2005 | CV | Market Commentary: Euronet prices upsized deal, TriZetto on deck; new US Airways' convertible gains; Incyte tumbles
|
9/28/2005 | BT | Market Commentary: Panacos, SkyePharma add to deal slate; Incyte, Endo drop on news; Electro-Optic rejigs talk, syndicate
|
8/15/2005 | BT | Market Commentary: Cita defers IPO plans for merger talks; Kosan dives on trial delays; Incyte, Abgenix buyers emerge
|
8/3/2005 | BT | Incyte reiterated by JMP at strong buy
|
8/1/2005 | CV | Incyte spends $28.4 million to buy back convertibles
|
7/25/2005 | BT | Market Commentary: Teva purchases Ivax, both higher; Endo Pharma climbs on possible sale of Ivax pain drug
|
7/25/2005 | BT | Incyte reiterated by JMP at strong buy
|
7/20/2005 | BT | Incyte maintained by Thomas Weisel at outperform
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
5/11/2005 | CV | Market Commentary: Delta bankruptcy seen inevitable; GM, Ford weigh financials, IPG; KV Pharma slammed; Red Hat up
|
11/4/2004 | CV | Incyte buys back $38.4 million 5.5% convertibles
|
4/27/2004 | CV | Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
|
3/8/2004 | CV | Incyte greenshoe exercised, raising convertibles to $250 million
|
2/13/2004 | CV | New Issue: Incyte upsized $200 million convertible yields 3.5%, up 35%
|
2/13/2004 | CV | Market Commentary: Adelphia bonds Earthbound, lose 6 points; Sirius, new paper active but slip to below par levels
|
2/12/2004 | CV | Incyte prices upsized $200 million convertibles to yield 31/2%, up 35%
|
2/12/2004 | CV | Market Commentary: Buyers propel new AMR convert; Bristol-Myers up on Erbitux news; Incyte trades at par in gray market
|
2/11/2004 | CV | Incyte $150 million convertible talked at 3.25-3.75% yield, up 32.5-37.5%
|
2/11/2004 | CV | Market Commentary: Disney steals show; Echostar cast as takeover target, too; Safeguard advanced
|
11/10/2003 | CV | Market Commentary: Biotech paper grabs attention as yield-hungry investors invade market
|